---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-079876"
form_type: "8-K"
ticker: "CATX"
cik: "0000728387"
company_name: "Perspective Therapeutics, Inc."
filed_at: "2025-05-30T23:59:59+00:00"
generated_at: "2026-05-20T05:13:02.612869+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Perspective Therapeutics reports updated Phase 1/2a data for [212Pb]VMT-α-NET in NETs at ASCO 2025

## Summary
- No dose-limiting toxicities, no discontinuations due to AEs, and no Grade 4/5 TEAEs in 42 treated patients.
- Four of seven patients in Cohort 2 had objective responses per RECIST v1.1; three confirmed, one pending confirmation.
- Seven of nine patients from Cohorts 1 and 2 remained progression-free after more than one year of follow-up.
- Safety acceptable: low-grade hematologic toxicities; all creatinine increases Grade 1; no serious renal complications.
- Cohort 2 re-opened in Aug 2024; 33 additional patients enrolled; company engaging FDA for further dose finding.

## SEC filing metadata
- accession: 0000950170-25-079876
- form_type: 8-K
- ticker: CATX
- cik: 0000728387
- company_name: Perspective Therapeutics, Inc.
- filed_at: 2025-05-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/728387/000095017025079876/0000950170-25-079876-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/728387/000095017025079876/catx-20250530.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-079876
- JSON: https://secwatch.observer/filing/0000950170-25-079876.json
- Plain text: https://secwatch.observer/filing/0000950170-25-079876.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.